



Erectile Dysfunction: The Problem Hiding Behind Prostate Cancer

Tarik Emre Sener* and Bahadır Sahin

Department of Urology, School of Medicine, Marmara University, Istanbul, Turkey

*Corresponding author: Sener TE, Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi, Uroloji Anabilim Dalı, 4. Kat. Fevzi Çakmak Mah. Muhsin Yazıcıoğlu Cad. Üst Kaynarca, Pendik, İstanbul, Türkiye, Tel: +905337620712; E-mail: dr.emresener@gmail.com

Received date: January 12, 2017; Accepted date: January 30, 2017; Published date: February 6, 2017

Copyright: © 2017 Sener TE, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Sener TE, Sahin B (2017) Erectile Dysfunction: The Problem Hiding Behind Prostate Cancer. *Reprod Syst Sex Disord* 6: 201. doi:10.4172/2161-038X.1000201

Letter to Editor

We read with great interest, the article written by Quaresima et al. evaluating the onset of erectile dysfunction (ED) in patients under active surveillance (AS) for low risk prostate cancer. We think that this topic is of huge importance, as ED affects enormously the quality of life in patients who are not under great threat by their primary illness in terms of mortality. Also, when a cancer diagnosis is on the table, many of the complaints that are not directly a cause of mortality are overlooked. Thus, investigating the AS patients for ED carries a significant importance to provide good health care.

Prostate cancer is a major health problem globally with 1,442,460 incident cases in 2013. It is the 8th leading cause of cancer death worldwide as developed countries are affected approximately twice more than developing countries [1]. Life expectancy in men has increased and taken into consideration the higher incidence of prostate cancer in elderly, the overall death from prostate cancer has doubled between 1990 and 2013 according to Dy et al. [1]. However, the mortality rate of untreated low risk prostate cancer with Gleason scores between 5-7 might be as low as 7% [2]. Thus, AS is becoming the way to manage patients with clinically confined, low risk prostate cancer without compromising curative treatment.

A prospective study is what scientific communities need now-a-days and is the appropriate way to investigate AS patients. The purpose of AS is to aim the correct timing for appropriate curative treatment without compromising curative intent, so patient follow-up must be both standardized for a predefined schedule and be individualized for each patient due to different co-morbidities and life-expectancies [3]. One of the largest cohorts with the longest follow-up including 993 patients demonstrated the safety profile of active surveillance as disease-specific survival is 98.1% and 94.3% at 10 and 15 years, respectively [4].

One of the major problems during AS, is the fear of disease progression with general anxiety. According to PRIAS study, this anxiety decreases after 18 months of AS [5]. Considering the co-occurrence of ED with anxiety, ED is rather an early problem of AS and this topic is already covered by Pearce et al. but using different parameters for erectile function assessment [6]. Quaresima et al. preferred the IIEF-5 questionnaire, which provided high sensitivity and specificity and is recommended by the European Association of Urology (EAU) Male Sexual Dysfunction Guidelines [7,8].

High body mass index, diabetes, hypertension and age have been pointed out as contributors to ED onset by the authors which is followed by their comment that a larger cohort is needed to support these findings. However, these factors have already been mentioned as risk factors by Pearle et al. as well as in the EAU Guidelines on Erectile Dysfunction [6,7].

In these contexts, we think the article by Quaresima et al. carries great importance regarding the approach towards patients that will undergo AS. Recognizing those AS patients under risk for ED can change our practice towards ameliorating our diagnostic and therapeutic approaches in terms of erectile function. The potential improvement in ED would decrease anxiety and ensure patients' well-being.

References

1. Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C (2017) Global Burden of urologic cancers, 1990-2013. *Eur Urol* 71: 437-446.
2. Albertsen PC (2015) Observational studies and the natural history of screen-detected prostate cancer. *Curr Opin Urol* 25: 232-237.
3. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, et al. (2016) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol pii: S0302-2838(16)30470-5*.
4. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, et al. (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. *J Clin Oncol* 33: 272-277.
5. Venderbos LD, van den Bergh RC, Roobol MJ, Schröder FH, Essink-Bot ML, et al. (2015) A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. *Psychooncology* 24: 348-354.
6. Pearce SM, Wang CHE, Victorson DE, Helfand BT, Novakovic KR, et al. (2015) A Longitudinal Study of Predictors of Sexual Dysfunction in Men on Active Surveillance for Prostate Cancer. *Sex Med* 3: 156-164.
7. Hatzimouratidis K, Eardley I, Giuliano F, Moncada I, Salonia A (2015) Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. *European Association of Urology*.
8. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology* 49: 822-830.